Stena Sessan invests in A3P Biomedical
Stena Sessan has during May 2022 invested in the Swedish prostate cancer diagnostics company A3P Biomedical. Following the investment Stena Sessan has become one of the company’s top 10 shareholders. The investment is part of Stena Sessan’s strategy of investing in a diversified portfolio of companies that have the potential to develop and grow for generations to come.
A3P Biomedical specialises in advanced prostate cancer diagnostics with the main product Stockholm3. Stockholm3 has been developed by scientists at Karolinska Institutet and validated in clinical studies encompassing more than 75 000 men. A3P Biomedical is now accelerating the commercialisation of Stockholm3, which has already replaced the standard PSA test at leading Nordic healthcare providers such as Capio S:t Görans Hospital in Stockholm and Stavanger University Hospital. The investment is part of A3P Biomedical’s latest financing round, broadening the investor base with new investors KinKon AB, Flerie Invest and The Foundation for Baltic and East European Studies alongside Stena Sessan.
The investment company Stena Sessan is part of the Stena Sphere and owned by the Olsson family. Through collaboration with co-owners, management teams and organisations, we help to develop businesses that can address the needs and challenges that the future holds. Our investment strategy is built on flexibility and a long-term investment horizon.